Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis

BackgroundNeoadjuvant chemotherapy has been accepted as an effective curative treatment for muscle-invasive bladder cancer patients and has resulted in better survival outcomes than radical cystectomy or a cisplatin-based regimen. In the present study, we aimed to compare the two most commonly used...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tiange Wu, Yuqing Wu, Shuqiu Chen, Jianping Wu, Weidong Zhu, Hui Liu, Ming Chen, Bin Xu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	bladder cancer neoadjuvant chemotherapy gemcitabine plus cisplatin methotrexate plus vinblastine plus doxorubicin plus cisplatin pathological response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9a5fcc5c565f4660bd58ef84a6227cd0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a5fcc5c565f4660bd58ef84a6227cd0
record_format	dspace
spelling	oai:doaj.org-article:9a5fcc5c565f4660bd58ef84a6227cd02021-12-01T01:58:12ZCurative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis2234-943X10.3389/fonc.2021.678896https://doaj.org/article/9a5fcc5c565f4660bd58ef84a6227cd02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.678896/fullhttps://doaj.org/toc/2234-943XBackgroundNeoadjuvant chemotherapy has been accepted as an effective curative treatment for muscle-invasive bladder cancer patients and has resulted in better survival outcomes than radical cystectomy or a cisplatin-based regimen. In the present study, we aimed to compare the two most commonly used cisplatin-based neoadjuvant chemotherapies, gemcitabine plus cisplatin and methotrexate plus vinblastine plus doxorubicin plus cisplatin, by summarizing and analyzing clinical data and outcomes of published research.MethodsWe searched for qualified studies that compared these two types of neoadjuvant chemotherapy, including 4 randomized controlled trials and 14 retrospective studies. Data and information on pathological responses and long-term survival studies were extracted and analyzed separately.ResultsA total of 18 studies with 3116 patients were selected from 1188 studies, which contained data on pathological complete response, pathological partial response, and overall survival. In contrast to the results of previous studies, there was no significant difference in pathological complete response (odds ratio, 0.97; 95% confidence interval, 0.81-1.15), pathological partial response (odds ratio, 0.85; 95% confidence interval, 0.72-1.14), and overall survival (hazard ratio, 0.99; 95% confidence interval, 0.83-1.17) between GC and MVAC in this meta-analysis.ConclusionNo significant differences were observed between GC and MVAC in the muscle-invasive bladder cancer treatment due to the similar curative effect and parallel long survival outcomes due to the similar curative effect and parallel long survival outcomes. The priority selection of GC or MVAC in the clinic should be guided by further investigation, and the clinical standard strategy still counts on the results of more randomized controlled trials in the future.Tiange WuTiange WuYuqing WuYuqing WuShuqiu ChenJianping WuWeidong ZhuHui LiuMing ChenMing ChenBin XuBin XuFrontiers Media S.A.articlebladder cancerneoadjuvant chemotherapygemcitabine plus cisplatinmethotrexate plus vinblastine plus doxorubicin plus cisplatinpathological responseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bladder cancer neoadjuvant chemotherapy gemcitabine plus cisplatin methotrexate plus vinblastine plus doxorubicin plus cisplatin pathological response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	bladder cancer neoadjuvant chemotherapy gemcitabine plus cisplatin methotrexate plus vinblastine plus doxorubicin plus cisplatin pathological response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tiange Wu Tiange Wu Yuqing Wu Yuqing Wu Shuqiu Chen Jianping Wu Weidong Zhu Hui Liu Ming Chen Ming Chen Bin Xu Bin Xu Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
description	BackgroundNeoadjuvant chemotherapy has been accepted as an effective curative treatment for muscle-invasive bladder cancer patients and has resulted in better survival outcomes than radical cystectomy or a cisplatin-based regimen. In the present study, we aimed to compare the two most commonly used cisplatin-based neoadjuvant chemotherapies, gemcitabine plus cisplatin and methotrexate plus vinblastine plus doxorubicin plus cisplatin, by summarizing and analyzing clinical data and outcomes of published research.MethodsWe searched for qualified studies that compared these two types of neoadjuvant chemotherapy, including 4 randomized controlled trials and 14 retrospective studies. Data and information on pathological responses and long-term survival studies were extracted and analyzed separately.ResultsA total of 18 studies with 3116 patients were selected from 1188 studies, which contained data on pathological complete response, pathological partial response, and overall survival. In contrast to the results of previous studies, there was no significant difference in pathological complete response (odds ratio, 0.97; 95% confidence interval, 0.81-1.15), pathological partial response (odds ratio, 0.85; 95% confidence interval, 0.72-1.14), and overall survival (hazard ratio, 0.99; 95% confidence interval, 0.83-1.17) between GC and MVAC in this meta-analysis.ConclusionNo significant differences were observed between GC and MVAC in the muscle-invasive bladder cancer treatment due to the similar curative effect and parallel long survival outcomes due to the similar curative effect and parallel long survival outcomes. The priority selection of GC or MVAC in the clinic should be guided by further investigation, and the clinical standard strategy still counts on the results of more randomized controlled trials in the future.
format	article
author	Tiange Wu Tiange Wu Yuqing Wu Yuqing Wu Shuqiu Chen Jianping Wu Weidong Zhu Hui Liu Ming Chen Ming Chen Bin Xu Bin Xu
author_facet	Tiange Wu Tiange Wu Yuqing Wu Yuqing Wu Shuqiu Chen Jianping Wu Weidong Zhu Hui Liu Ming Chen Ming Chen Bin Xu Bin Xu
author_sort	Tiange Wu
title	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
title_short	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
title_full	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
title_fullStr	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed	Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
title_sort	curative effect and survival assessment comparing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant therapy for bladder cancer: a systematic review and meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9a5fcc5c565f4660bd58ef84a6227cd0
work_keys_str_mv	AT tiangewu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT tiangewu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT yuqingwu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT yuqingwu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT shuqiuchen curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT jianpingwu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT weidongzhu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT huiliu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT mingchen curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT mingchen curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT binxu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis AT binxu curativeeffectandsurvivalassessmentcomparinggemcitabineandcisplatinversusmethotrexatevinblastinedoxorubicinandcisplatinasneoadjuvanttherapyforbladdercancerasystematicreviewandmetaanalysis
_version_	1718405977894551552

Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis

Ejemplares similares